No doubt about it. That is the purpose of underwriting -- to place those shares -- make your clients happy. I expect $15 by year end, $18 to $20 post PDUFA and $25 TO $30 BY YEAR END 2015.
I believe 3 or 4 were neuphrologists... and the rest were oncologists. So I still thought"WE" WERE outnumbered. But I do think most have been waiting for something like this. The statistician for the fda was so caught up in the forest, she could set the big picture. ..the fda clinician saw efficacy and safety, the statistician just numbers.
I would expect a volatile day or at least I'm hoping. I missed my opportunity to buy more yesterday because I didn't want to chase. But will buy with a pullback if it happens
Molloy has seen thousands of these. He's a good analyst, but apparently not the only one who see this as a favorable. We had 3 million votes yesterday. And that was most purchases (not covers) as it progressed up ward in an orderly fashion.
google Jim cramer how to manipulate the market. The ones who sell He calls "Moron Longs". This is all smoke and mirrors, positive adcom will squeeze the shorts and this unethical activity provides a buying opportunity for those with cash.
Good Luck....this could hit $8 Today.
With Frozen and Frozen 2 coming...Somebody just might get interested.
Isn't there a less favorable out with the oncologic Adcom board review? Even if renal is a "done deal", any outcome not stellar (i.e. not approved for cancer patients yet or needs more tecting for cancer patients) will hit pps. Why not just go the renal route and get positive income? Does Rockwell decide which board reviews SFP or FDA? THanks for your insight renal people!
Drug Evaluation and Research.
On March 9, 2007, we issued a public health advisory to alert you that recent reports of studies with the use of Erythropoiesis [ee-RITH-row-poe-EE-sis] -stimulating agents (or ESAs) have shown a higher chance of serious and life-threatening side effects and a greater number of deaths in patients treated with these agents.
Marketed under the trade names Aranesp, Epogen and Procrit, ESAs stimulate the bone marrow to make more red blood cells. We have approved them for use in reducing the need for blood transfusions in patients with chronic kidney failure, cancer patients on chemotherapy, patients scheduled for major surgery (except heart surgery) and patients with HIV who are using AZT.
Because all ESAs work the same way, the findings from these studies apply to all ESAs. We are re-evaluating the safe use of ESAs.
FDA and Amgen, the manufactuer of the three ESA-agents, have changed the full prescribing information for these drugs. The new product labeling includes a new boxed warning, updated warning, and change to the dosage and adminstration sections for all ESAs.
We are asking health-care professionals to report serious adverse events in connection with ESAs to us through the MedWatch program by phone at 1-800-F-D-A-ten-88 or by the Internet at F-D-A dot G-O-V slash MedWatch.
To hear the full public health advisory, listen to part 2 of this broadcast. Updated information about drugs with emerging safety concerns is available 24 hours a day at our Web site F-D-A dot G-O-V slash C-D-E-R.
prefer no dilution...under $9.55 is ok with me. cash burn is very small. Calcitriol will put RMTI cash flow positive
never a fan of dilution and burn rate is so small now. Calcitriol sales will 10x the 1 mil qtrly burn rate. needs to get over 9.55 for exercise to even be a consideration